---
figid: PMC9627417__jamanetwopen-e2239336-g002
pmcid: PMC9627417
image_filename: jamanetwopen-e2239336-g002.jpg
figure_link: /pmc/articles/PMC9627417/figure/zoi221114f2/
number: Figure 2.
figure_title: Use of Expedited Drug Development and Review Programs Among Novel Drug–Indication
  Pairs Approved From 2008 to 2021, by Therapeutic Area
caption: Numbers in the circles are the number of novel drug–indication pairs that
  used each program type; larger circles signify greater numbers of pairs. AA indicates
  Accelerated Approval pathway; BT, Breakthrough Therapy designation; FT, Fast Track
  designation; and PR, Priority Review designation.
article_title: Use of US Food and Drug Administration Expedited Drug Development and
  Review Programs by Orphan and Nonorphan Novel Drugs Approved From 2008 to 2021.
citation: Andrea N. Monge, et al. JAMA Netw Open. 2022 Nov;5(11):e2239336.
year: '2022'

doi: 10.1001/jamanetworkopen.2022.39336
journal_title: JAMA Network Open
journal_nlm_ta: JAMA Netw Open
publisher_name: American Medical Association

keywords:
---
